[조사자료] 글로벌 안티센스 및 RNAi 치료제 시장 (2023-2030) : RNA 간섭, 안티센스 RNA

■ 영문 제목 : Antisense & RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology, By Application, By Route Of Administration, By Region, And Segment Forecasts, 2023 - 2030
	■ 상품코드 : GRV23NOV001 ■ 조사/발행회사 : Grand View Research ■ 발행일 : 2023년 9월 ■ 페이지수 : 160 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 (납기:3일) ■ 조사대상 지역 : 세계 ■ 산업 분야 : 의약품

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User (1인 열람용)	USD5,950 ⇒환산￦8,032,500	견적의뢰/주문/질문
Multi User (5인 열람용)	USD6,950 ⇒환산￦9,382,500	견적의뢰/주문/질문
Global/corporate License (기업 열람용)	USD8,950 ⇒환산￦12,082,500	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

글로벌 안티센스 및 RNAi 치료제 시장의 성장과 동향
Grand View Research사의 최신 보고서에 따르면, 세계의 안티센스 및 RNAi 치료제 시장 규모는 2023년부터 2030년까지 연평균 18. 06%의 성장률로 확대되어 2030년에는 142. 5억 달러에 달할 것으로 예상됩니다. 생물학적 벡터와 나노기술의 개발, 새로운 약물 분자의 출시를 포함한 임상 연구에 대한 자금 지원의 증가는 제품 개발에서 중요하며 시장 확대의 원동력이 되고 있습니다.

다국적 의료 기관들은 다양한 질병에 대한 인식을 높이고 새로운 치료법 개발을 지원하고 있습니다. 민간 연구기관과 기업들이 연구기관을 지원하는 형태로 임상 시험에 참여하는 것도 이 분야 확장에 큰 도움이 될 것으로 예상됩니다. 예를 들어, 2022년 3월 바이오젠(Biogen Inc.)과 아이오니스 파마슈티컬스(Ionis Pharmaceuticals, Inc.)는 근위축성 측삭경화증(ALS) 환자를 대상으로 한 항센스 올리고뉴클레오타이드의 임상 1상 시험 결과를 발표하였습니다. 업계 관계자들은 이러한 임상 시험의 증가는 안티센스 및 RNAi 치료 기반 제품 출시를 증가시켜 시장 성장을 촉진할 것으로 예상하고 있습니다.

안티센스 및 RNAi 치료는 세포의 성장 주기에 영향을 미치고 핵산을 표적으로 하는 다양한 질병을 치료하는 데 사용될 수 있습니다. 유전자 발현을 재생하고 단백질 생산을 조절하는 miRNA의 능력은 결과적으로 산업 발전에 영향을 미쳐 큰 주목을 받고 있습니다. 미국 과학진흥협회(American Association for the Advancement of Science)가 2023년 7월 발표한 논문에 따르면, 미국 매사추세츠 공과대학(UMass Chan Medical School)과 러쉬대학교 메디컬센터(RUSH University Medical Center) RUSH University Medical Center)가 개발한 안티센스 요법이 취약 X 증후군(fragile X syndrome) 환자에서 채취한 세포 표본에서 FMRP라는 단백질의 생성을 회복시키는 데 유용한 것으로 나타났다고 밝혔습니다. 이러한 업계의 발전은 예측 기간 동안 많은 질병을 치료하기 위한 RNAi 및 안티센스 치료제에 대한 수요를 촉진할 것으로 예상됩니다.

안티센스 및 RNAi 치료제 시장 보고서 하이라이트

- 안티센스 RNA 기술은 신경 퇴행성 질환 및 유전성 질환과 같은 질병에 광범위하게 적용되어 기술 분야에서 2022년 가장 큰 매출 점유율을 차지했습니다.

- RNA 간섭 분야는 기술 분야에서 가장 빠르게 성장할 것으로 예상됩니다. 이 기술은 다시 siRNA와 miRNA로 나뉘는데, miRNA는 세포의 정체성 유지에 중요한 역할을 하기 때문에 암의 확산을 더 잘 이해하기 위해 채택되고 있습니다.

- 용도별로는 유전질환 분야가 38. 9%의 매출 점유율로 시장을 주도했습니다. 이 부문의 우위는 주요 기업들이 새로운 유전병 치료제 개발에 점점 더 집중하고 있기 때문입니다.

- 투여 경로별로는 척수강 내 주사가 2022년 매출에서 44. 6%의 점유율을 차지했습니다. 척추 마취, 화학 요법, 통증 관리에 널리 사용되는 것이 이 부문의 우위를 차지하게 된 원인입니다.

- 북미는 항센스 및 RNAi 치료제의 세계 시장에서 가장 큰 매출 점유율을 차지했습니다. 이 지역의 우위는 이 지역에 여러 플레이어가 존재하고 업계에서 입지를 강화하기 위해 노력하고 있기 때문입니다.

- 유럽은 세카르나(Secarna)와 같은 주요 기업들이 이 지역에서 사업을 확장하고 있기 때문에 2023년부터 2030년까지 예측 기간 동안 가장 빠른 성장을 기록할 것으로 예상됩니다.

■ 보고서 개요

Chapter 1. 조사 방법 및 범위
Chapter 2. 개요
Chapter 3. 시장 변수, 동향, 범위
Chapter 4. 세계의 안티센스 및 RNAi 치료제 시장 : 기술별 분석
Chapter 5. 세계의 안티센스 및 RNAi 치료제 시장 : 용도별 분석
Chapter 6. 세계의 안티센스 및 RNAi 치료제 시장 : 투여 경로별 분석
Chapter 7. 세계의 안티센스 및 RNAi 치료제 시장 : 지역별 분석
Chapter 8. 경쟁 현황

■ 보고서 목차

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Market Definitions
1.2. Regional Scope
1.3. Estimates & Forecasts Timeline
1.4. Objectives
1.4.1. Objective 1
1.4.2. Objective 2
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased database
1.6.2. GVR’s internal database
1.6.3. Secondary sources
1.6.4. Primary research
1.7. Information or Data Analysis
1.7.1. Data analysis models
1.8. Marker Formulation & Validation
1.9. Market Model
1.9.1. Commodity flow analysis
1.10. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Presence of strong pipeline product portfolio
3.2.1.2. Introduction of technological advancements in drug delivery
3.2.1.3. Implementation of favorable government initiatives & external funding for R&D exercises
3.2.1.4. Rising collaborations between pharmaceutical companies
3.2.2. Market Restraint Analysis
3.2.2.1. Expensive and tedious research programs
3.2.2.2. Delivery of RNAi therapeutics and off-target effects
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Technology Business Analysis
4.1. Antisense and RNAi Therapeutics Market: Technology Movement Analysis
4.2. RNA Interference
4.2.1. RNA Interference Market, 2018 – 2030 (USD Million)
4.3. Antisense RNA
4.3.1. Antisense RNA Market, 2018 – 2030 (USD Million)
Chapter 5. Application Business Analysis
5.1. Antisense and RNAi Therapeutics Market: Application Movement Analysis
5.2. Ocular
5.2.1. Ocular Market, 2018 – 2030 (USD Million)
5.3. Cardio metabolic & Renal Disorders
5.3.1. Cardio metabolic & Renal Disorders Market, 2018 – 2030 (USD Million)
5.4. Respiratory Disorders
5.4.1. Respiratory Disorders Market, 2018 – 2030 (USD Million)
5.5. Cancer
5.5.1. Cancer Market, 2018 – 2030 (USD Million)
5.6. Neurodegenerative Disorders
5.6.1. Neurodegenerative Disorders Market, 2018 – 2030 (USD Million)
5.7. Genetic Disorders
5.7.1. Genetic Disorders Market, 2018 – 2030 (USD Million)
5.8. Infectious Diseases
5.8.1. Infectious Diseases Market, 2018 – 2030 (USD Million)
5.9. Skin Diseases
5.9.1. Skin Diseases Market, 2018 – 2030 (USD Million)
5.10. Other
5.10.1. Other Market, 2018 – 2030 (USD Million)
Chapter 6. Route of Administration Business Analysis
6.1. Antisense and RNAi Therapeutics Market: Route of Administration Movement Analysis
6.2. Intravenous Injections
6.2.1. Intravenous Injections Market, 2018 – 2030 (USD Million)
6.3. Intrathecal Injections
6.3.1. Intrathecal Injections Market, 2018 – 2030 (USD Million)
6.4. Subcutaneous Injections
6.4.1. Subcutaneous Injections Market, 2018 – 2030 (USD Million)
6.5. Others
6.5.1. Others Market, 2018 – 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Antisense and RNAi Therapeutics Market Share By Region, 2022 & 2030
7.2. North America
7.2.1. North America Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Target Disease Prevalence
7.2.2.3. Competitive Scenario
7.2.2.4. Regulatory Framework
7.2.2.5. U.S. Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Target Disease Prevalence
7.2.3.3. Competitive Scenario
7.2.3.4. Regulatory Framework
7.2.3.5. Canada Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3. Europe
7.3.1. Europe Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Target Disease Prevalence
7.3.2.3. Competitive Scenario
7.3.2.4. Regulatory Framework
7.3.2.5. UK Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Target Disease Prevalence
7.3.3.3. Competitive Scenario
7.3.3.4. Regulatory Framework
7.3.3.5. Germany Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Target Disease Prevalence
7.3.4.3. Competitive Scenario
7.3.4.4. Regulatory Framework
7.3.4.5. France Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Target Disease Prevalence
7.3.5.3. Competitive Scenario
7.3.5.4. Regulatory Framework
7.3.5.5. Italy Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Target Disease Prevalence
7.3.6.3. Competitive Scenario
7.3.6.4. Regulatory Framework
7.3.6.5. Spain Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Key Country Dynamics
7.3.7.2. Target Disease Prevalence
7.3.7.3. Competitive Scenario
7.3.7.4. Regulatory Framework
7.3.7.5. Denmark Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Key Country Dynamics
7.3.8.2. Target Disease Prevalence
7.3.8.3. Competitive Scenario
7.3.8.4. Regulatory Framework
7.3.8.5. Sweden Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Key Country Dynamics
7.3.9.2. Target Disease Prevalence
7.3.9.3. Competitive Scenario
7.3.9.4. Regulatory Framework
7.3.9.5. Norway Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Competitive Scenario
7.4.2.4. Regulatory Framework
7.4.2.5. Japan Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Competitive Scenario
7.4.3.4. Regulatory Framework
7.4.3.5. China Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Competitive Scenario
7.4.4.4. Regulatory Framework
7.4.4.5. India Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Target Disease Prevalence
7.4.5.3. Competitive Scenario
7.4.5.4. Regulatory Framework
7.4.5.5. Australia Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Target Disease Prevalence
7.4.6.3. Competitive Scenario
7.4.6.4. Regulatory Framework
7.4.6.5. Thailand Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Target Disease Prevalence
7.4.7.3. Competitive Scenario
7.4.7.4. Regulatory Framework
7.4.7.5. South Korea Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Competitive Scenario
7.5.2.4. Regulatory Framework
7.5.2.5. Brazil Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Competitive Scenario
7.5.3.4. Regulatory Framework
7.5.3.5. Mexico Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Competitive Scenario
7.5.4.4. Regulatory Framework
7.5.4.5. Argentina Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.6. MEA
7.6.1. MEA Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Competitive Scenario
7.6.2.4. Regulatory Framework
7.6.2.5. South Africa Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Competitive Scenario
7.6.3.4. Regulatory Framework
7.6.3.5. Saudi Arabia Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Competitive Scenario
7.6.4.4. Regulatory Framework
7.6.4.5. UAE Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Competitive Scenario
7.6.5.4. Regulatory Framework
7.6.5.5. Kuwait Antisense and RNAi Therapeutics Market, 2018 – 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2022
8.4. Company Profiles/Listing
8.4.1. Olix Pharmaceuticals
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. GSK plc.
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Sanofi Aventis / Genzyme
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Alnylam Pharmaceuticals
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Isis Pharmaceuticals/ Ionis Pharmaceuticals
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. Benitec Biopharma Ltd.
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Arbutus Biopharma Ltd.
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Silence Therapeutics
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Bio-Path Holdings Inc.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Antisense Therapeutics Limited.
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 4 Global Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 5 Global Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 6 Global Antisense and RNAi Therapeutics Market, By Region, 2018 - 2030 (USD Million)
Table 7 North America Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 8 North America Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 9 North America Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 10 North America Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 11 U.S. Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 12 U.S. Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 13 U.S. Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 14 Canada Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 15 Canada Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 16 Canada Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 17 Europe Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 18 Europe Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 19 Europe Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 20 Europe Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 21 UK Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 22 UK Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 23 UK Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 24 Germany Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 25 Germany Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 26 Germany Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 27 France Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 28 France Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 29 France Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 30 Spain Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 31 Spain Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 32 Spain Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 33 Italy Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 34 Italy Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 35 Italy Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 36 Denmark Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 37 Denmark Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 38 Denmark Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 39 Norway Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 40 Norway Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 41 Norway Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 42 Sweden Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 43 Sweden Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 44 Sweden Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 45 Asia Pacific Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 48 Asia Pacific Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 49 China Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 50 China Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 51 China Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 52 Japan Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 53 Japan Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 54 Japan Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 55 India Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 56 India Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 57 India Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 58 South Korea Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 59 South Korea Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 60 South Korea Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 61 Australia Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 62 Australia Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 63 Australia Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 64 Thailand Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 65 Thailand Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 66 Thailand Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 67 Latin America Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 68 Latin America Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 69 Latin America Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 70 Latin America Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 71 Brazil Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 72 Brazil Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 73 Brazil Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 74 Mexico Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 75 Mexico Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 76 Mexico Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 77 Argentina Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 78 Argentina Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 79 Argentina Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 80 MEA Antisense and RNAi Therapeutics Market, By Country, 2018 - 2030 (USD Million)
Table 81 MEA Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 82 MEA Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 83 MEA Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 84 South Africa Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 85 South Africa Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 86 South Africa Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 87 UAE Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 88 UAE Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 89 UAE Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 90 Saudi Arabia Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 91 Saudi Arabia Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 92 Saudi Arabia Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
Table 93 Kuwait Antisense and RNAi Therapeutics Market, By Technology, 2018 - 2030 (USD Million)
Table 94 Kuwait Antisense and RNAi Therapeutics Market, By Application, 2018 - 2030 (USD Million)
Table 95 Kuwait Antisense and RNAi Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)

※본 조사보고서 [글로벌 안티센스 및 RNAi 치료제 시장 (2023-2030) : RNA 간섭, 안티센스 RNA] (코드 : GRV23NOV001) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [글로벌 안티센스 및 RNAi 치료제 시장 (2023-2030) : RNA 간섭, 안티센스 RNA] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

세계의 안티센스 및 RNAI 치료제 시장 2024-2030 : RNA 간섭, 안티센스 RNA
GRV24JNU115 / Grand View Research / 2023년 12월 / 글로벌 안티센스 및 RNAI 치료제 시장의 성장과 동향 Grand View Research, Inc.사의 최신 보고서에 따르면, 세계의 안티센스 및 RNAI 치료제 시장 규모는 2024년부터 2030년까지 18.12%의 CAGR을 기록하며 2030년까지 146.6억 달러에...1. 조사 방법 및 범위 2. 개요 3. 세계의 안티센스 및 RNAI 치료제 시장 변수, 동향 및 범위 4. 세계의 안티센스 및 RNAI 치료제 시장 규모 : 기술별 예측 및 동향 분석 5. 세계의 안티센스 및 RNAI 치료제 시장 규모 : 용도별 예측 및 동향 분석 6. 세계의 안티센스 및...

세계의 아데노 수반 바이러스 벡터 제조 시장 (2023~2030) : 임상, 상업
GRV23MR008 / Grand View Research / 2023년 2월 / 미국 Grand View Research (그랜드뷰리서치)의 본 조사 보고서는 세계의 아데노 수반 바이러스 벡터 제조 시장 규모가 2023년부터 2030년 사이에 CAGR 22.5% 증가하여, 2030년에는 39.5억 달러에 달할 것으로 예상하고 있습니다. 본...Adeno Associated Virus Vector Manufacturing Market Growth & Trends The global adeno associated virus vector manufacturing market size is expected to reach USD 3.95 billion by 2030, registering a CAGR of 22.5% over the forecast period, according to a new report by Grand View Research, Inc. This growth is attributed...

글로벌 로봇 보조 내시경 시장 (2023-2030) : 병원, 외래 환자 시설
GRV23NOV241 / Grand View Research / 2023년 9월 / 글로벌 로봇 보조 내시경 시장의 성장과 동향 Grand View Research사의 최신 보고서에 따르면, 세계의 로봇 보조 내시경 시장 규모는 2023년부터 2030년까지 연평균 8. 2%의 성장률을 기록하여 2030년에는 23억 6천만 달러에...Chapter 1. 조사 방법 및 범위 Chapter 2. 개요 Chapter 3. 시장 변동, 동향, 범위 Chapter 4. 세계의 로봇 보조 내시경 시장 : 최종 용도별 예측 및 동향 분석 Chapter 5. 세계의 로봇 보조 내시경 시장 : 지역별 예측 및 동향 분석 Chapter 6. 경쟁 현황...

세계의 펩티드 마이크로어레이 시장 (2023~2030) : 질환 진단, 단백질 기능 분석
GRV23MA024 / Grand View Research / 2023년 1월 / 미국 Grand View Research (그랜드뷰리서치)는 세계의 펩티드 마이크로어레이 시장 규모가 2023년부터 2030년 사이에 연평균 4.51% 성장하여, 2030년에는 1,133.5백만 달러에 달할 것으로 예측하고 있습니다. 본 조사 자료는 세계의 펩티드 마이크로어레이 시장을...Peptide Microarray Market Growth & Trends The global peptide microarray market size is expected to reach USD 1,133.5 million by 2030, registering a CAGR of 4.51% over the forecast period, according to a new report by Grand View Research, Inc. The market is expected to witness a stable growth rate...

세계의 맞춤형 항체 시장 (2023~2030) : 단클론 항체, 폴리클로날 항체, 재조합 항체, 기타
GRV23MR076 / Grand View Research / 2023년 2월 / 미국 Grand View Research (그랜드뷰리서치)의 본 조사 보고서는 세계의 맞춤형 항체 시장 규모가 2023년부터 2030년 사이에 CAGR 9.7% 증가하여, 2030년에는 301.7백만 달러에 이를 것으로 예상하고 있습니다. 본 자료는 세계의 맞춤형...Custom Antibody Market Growth & Trends The global custom antibody market size is expected to reach USD 301.7 million by 2030, expanding at a CAGR of 9.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is expected to witness substantial growth during...